IMMX
NASDAQImmix Biopharma Inc.
Website
News25/Ratings3
News · 26 weeks29-56%
2025-10-262026-04-19
Mix1590d
- SEC Filings8(53%)
- Other4(27%)
- Analyst3(20%)
Latest news
25 items- PRImmix Biopharma to Participate in the Jefferies Global Healthcare ConferenceLOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc.Immix Bio
- SECSEC Form DEFA14A filed by Immix Biopharma Inc.DEFA14A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form DEF 14A filed by Immix Biopharma Inc.DEF 14A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECImmix Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Immix Biopharma Inc.10-K/A - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form S-8 filed by Immix Biopharma Inc.S-8 - Immix Biopharma, Inc. (0001873835) (Filer)
- SECImmix Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form 424B5 filed by Immix Biopharma Inc.424B5 - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form 10-K filed by Immix Biopharma Inc.10-K - Immix Biopharma, Inc. (0001873835) (Filer)
- ANALYSTMorgan Stanley initiated coverage on Immix Biopharma with a new price targetMorgan Stanley initiated coverage of Immix Biopharma with a rating of Overweight and set a new price target of $20.00
- SECSEC Form SCHEDULE 13G filed by Immix Biopharma Inc.SCHEDULE 13G - Immix Biopharma, Inc. (0001873835) (Subject)
- ANALYSTCitizens initiated coverage on Immix Biopharma with a new price targetCitizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00
- PRImmix Biopharma to Participate in Upcoming Investor ConferencesLOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences: Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL. The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL. Company management will host one-on-one meetings during the conferences. Interested investors should contact their Leerink or Citizens representative to request meetings. A link to access replays, when a
- SECSEC Form SCHEDULE 13G filed by Immix Biopharma Inc.SCHEDULE 13G - Immix Biopharma, Inc. (0001873835) (Subject)
- ANALYSTMizuho initiated coverage on Immix Biopharma with a new price targetMizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00
- SECSEC Form EFFECT filed by Immix Biopharma Inc.EFFECT - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form S-3 filed by Immix Biopharma Inc.S-3 - Immix Biopharma, Inc. (0001873835) (Filer)
- INSIDERSEC Form 4 filed by Director Chang Nancy T4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERCEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- INSIDERCFO Morris Gabriel S exercised 156,000 in-the-money shares at a strike of $0.80 and bought $5,067 worth of shares (770 units at $6.58), increasing direct ownership by 0.26% to 291,429 units (SEC Form 4)4 - Immix Biopharma, Inc. (0001873835) (Issuer)
- PRImmix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the
- SECImmix Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form 424B5 filed by Immix Biopharma Inc.424B5 - Immix Biopharma, Inc. (0001873835) (Filer)
- SECSEC Form FWP filed by Immix Biopharma Inc.FWP - Immix Biopharma, Inc. (0001873835) (Subject)
- SECImmix Biopharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Immix Biopharma, Inc. (0001873835) (Filer)